Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
5.39
+0.39 (7.80%)
At close: Aug 12, 2026, 4:00 PM EDT
5.34
-0.05 (-0.92%)
After-hours: Aug 12, 2026, 5:34 PM EDT
Unicycive Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Upcoming PDUFA for oxylanthanum carbonate could enable a differentiated, low pill burden therapy for hyperphosphatemia in dialysis patients, with strong clinical data and a focused commercialization plan. Financial runway and reimbursement strategies support near-term launch.
Fiscal Year 2025
-
OLC, a therapy for hyperphosphatemia in dialysis patients, faces a regulatory delay due to a third-party manufacturing issue, not drug safety or efficacy. Commercial launch is planned soon after approval, with strong funding and a focused sales strategy.